Levodopa challenge test for Parkinson's disease and other parkinsonian syndromes

Levodopa challenge test for Parkinson's disease and other parkinsonian syndromes - Levodopa challenge test for Parkinson's disease and other parkinsonian syndromes

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007896

Enrollment

100

Registered

2012-05-07

Start date

2012-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson&#39

Interventions

The patients are given domperidone 30 mg/day for 3 days. When a patient is already on any anti-parkinson drugs, these drugs were withdrawn from the night before of the evaluation day. On the fourth da

s Disease Rating Scale motor scores by a clinician who is blind to the test drug. The patients are given domperidone 30 mg/day (standard dose in Japan) for 3 days. When a patient is already on any ant

s Disease Rating Scale motor scores by a clinician who is blind to the test drug.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: A consecutive series of patients admitted to our hospital for diagnostic and/or treatment purpose, who presented with extrapyramidal symptoms

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
The improvement of Unified Parkinson's Disease Rating Scale motor scores	—

Countries

Japan

Contacts

Public ContactHirofumi Kusaka, Reika Wate

Kansai Medical University Dept. of Neurology

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

Levodopa challenge test for Parkinson&#39;s disease and other parkinsonian syndromes